Home  /  Resource Library  /  A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF PARSACLISIB, A PI3K INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN CHINA: UPDATED RESULTS FROM THE STUDY

A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF PARSACLISIB, A PI3K INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN CHINA: UPDATED RESULTS FROM THE STUDY

EHA 2023